Why does the speaker consider the BRUIN data for pirtobrutinib particularly valuable in R/R marginal zone lymphoma?
BRUIN was a randomized trial showing pirtobrutinib is superior to CAR T-cell therapy after a covalent BTK inhibitor.
It provides marginal zone lymphoma-specific data after prior covalent BTK inhibitor therapy, in a disease where treatment is often extrapolated from follicular lymphoma trials.
It supports pirtobrutinib as the preferred first-line BTK inhibitor in marginal zone lymphoma, ahead of covalent BTK inhibitors.